Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvastatic Adjuvant Therapy in COVID-19
NCT04542447Phase 1Unknown
- Sponsor
- Natureceuticals
- Start
- Sep 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Nuvastatic + SOC with Placebo + SOC (2 arms). Primary endpoints: Time to clinical improvement up to 28 days, Safety and Efficacy of Nuvastatic at 14 Days and 7 more. Status: unknown.
02
Drugs
Nuvastatic
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04542447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542447.